Johnson & Johnson Aktie
131,06EUR | 3,86EUR | 3,03% |
Aktionärsstruktur
Inhaber | in % |
---|---|
Freefloat | 99,86 |
The Vanguard Group, Inc. | 8,66 |
Vanguard Group, Inc. (Subfiler) | 8,22 |
State Street Corp. | 5,47 |
Vanguard Total Stock Market Index Fund | 2,83 |
BlackRock Institutional Trust Co. NA | 2,35 |
BlackRock Fund Advisors | 2,35 |
Vanguard 500 Index Fund | 2,01 |
Geode Capital Management LLC | 1,52 |
Wellington Management Co. LLP | 1,35 |
State Farm Investment Management Corp. | 1,31 |
Northern Trust Corp. | 1,24 |
Massachusetts Financial Services Co. | 1,07 |
Norges Bank (13F) | 1,05 |
Government Pension Fund - Global (The) | 1,03 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
2016 | 2017 | 2018 | 2019 | 2020 | |
---|---|---|---|---|---|
Personal am Ende des Jahres | 126 400 | 134 000 | 135 100 | 132 200 | 134 500 |
Umsatz pro Mitarbeiter in Mio. EUR | 0,57 | 0,57 | 0,60 | 0,62 | 0,61 |
Bilanz (in Mio. EUR) - Aktiva
2016 | 2017 | 2018 | 2019 | 2020 | |
---|---|---|---|---|---|
Summe Umlaufvermögen | 65 032 | 43 088 | 46 033 | 45 274 | 51 237 |
Summe Anlagevermögen | 97 544 | 94 741 | 90 232 | 88 152 | 99 644 |
Summe Aktiva | 141 208 | 157 303 | 152 954 | 157 728 | 174 894 |
Bilanz (in Mio. EUR) - Passiva
2016 | 2017 | 2018 | 2019 | 2020 | |
---|---|---|---|---|---|
Gesamtverschuldung/ -verbindlichkeiten | 27 126 | 34 581 | 30 480 | 28 681 | 36 366 |
Summe Fremdkapital | 70 790 | 97 143 | 93 202 | 98 257 | 111 616 |
Summe Eigenkapital | 70 418 | 60 160 | 59 752 | 59 471 | 63 278 |
Summe Passiva | 141 208 | 157 303 | 152 954 | 157 728 | 174 894 |
Adresse
One Johnson & Johnson Plaza, 08933 New Brunswick | |
Telefon | +1 (732) 524-0400 |
Internet | http://www.jnj.com |
Management
A. Eugene Washington
Independent Director |
Alex Gorsky
Chairman & Chief Executive Officer |
Anne M. Mulcahy
Lead Independent Director |
Ashley A. McEvoy
Executive VP & Worldwide Chairman-Medical Devices |
Charles O. Prince
Independent Director |
Chris DelOrefice
Vice President-Investor Relations |
Ciro Römer
Company Group Chairman |
D. Scott Davis
Independent Director |
Euan Stuart Thomson
Global Head-Digital Technology |
Frederic H. Moll
Chief Development Officer |
Hubert Joly
Independent Director |
Ian Edward Lamert Davis
Independent Director |
James D. Swanson
Global Chief Information Officer & Executive VP |
Jennifer A. Doudna
Independent Director |
Jennifer Taubert
EVP & Worldwide Chairman-Pharmaceuticals |
Joaquin Duato
Vice Chairman-Executive Committee |
Joseph J. Wolk
Chief Financial Officer & Executive Vice President |
Kathleen M. Widmer
Chairman-Consumer North America |
Lisa Romanko
Senior Director-Investor Relations |
Marillyn A. Hewson
Independent Director |
Mark Alan Weinberger
Independent Director |
Mark B. McClellan
Independent Director |
Mary C. Beckerle
Independent Director |
Mathai Mammen
Head-Science & Development |
Matthew Orlando
Secretary |
Matthew Stuckley
Senior Finance Director |
Michael E. Sneed
Chief Communication Officer & Executive VP |
Michael H. Ullmann
Executive Vice President & General Counsel |
Nadja Y. West
Director |
Paulus Stoffels
Chief Scientific Officer |
Peter M. Fasolo
Chief Human Resources Officer & Executive VP |
Peter Shen
Global Head-Research & Development |
Robert J. Decker
Chief Accounting Officer & Controller |
Ronald A. Kapusta
Chief Accounting Officer & Controller |
Ronald A. Williams
Independent Director |
Sarah L. Colamarino
Vice President-Corporate Equity |
Scott White
Company Group Chairman |
Thomas J. Spellman
Secretary |